NCT04683484View on ClinicalTrials.gov

A Clinical Trial to Assess the Safety and Immunogenicity of Nanocovax in Heathy Volunteers

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

620

Participants

Timeline

Start Date

December 10, 2020

Primary Completion Date

June 10, 2021

Study Completion Date

August 10, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

Nanocovax

Recombinant Protein spike (s) SARS-CoV-2 and adjuvant (0,5 mg Al PO4)

BIOLOGICAL

Placebo

0,5 mg Al PO4

Trial Locations (1)

Unknown

RECRUITING

Military Medical Academy, Hanoi

Sponsors
All Listed Sponsors
lead

Nanogen Pharmaceutical Biotechnology Joint Stock Company

INDUSTRY